Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Endothelin receptor antagonistPhenylpropionatesPyrimidines

Narrower (1)

LU 135252

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
BACKGROUND Hypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2008
2008
Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist
Objective: To summarize the role of the endothelin system (ETS) in cardiovascular disease (CVD) and evaluate the potential… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo…
BACKGROUND Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
The cause of focal-segmental glomerulosclerosis as a consequence of physiological aging, which is believed to be inexorable, is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats.
The present study evaluated the effects of long-term treatment with the endothelin A (ET(A)) receptor antagonist darusentan… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
BACKGROUND The antihypertensive efficacy and safety of darusentan, a new selective endothelin, antagonist was investigated… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
BACKGROUND The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE